Stock listing
NASDAQ:JANX Janux Therapeutics, Inc. Stock
Home listing (NASDAQ) of Janux Therapeutics, Inc.
Follow Janux Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:JANX
$10.08 USD -0.23 (-2.2%)
Close on Nov 20, 2026
- Day range
- $10.05 – $10.54 USDNov 20, 2026
- Volume
- 1.11M sharesNov 20, 2026
- Market cap
- $616.7M USDAt the close on Nov 20, 2026 · price × 61.18M shares outstanding
- 52-week range
- $10.05 – $35.34 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15.74M USDMedian day 810,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:JANX · Home | $10.08 USD | -0.23 (-2.2%) | 1,114,707 | $10.16 | $10.54 | $10.05 | $10.31 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JANX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.08 | -0.23 | -2.2% | $10.16 | $10.54 | $10.05 | 1,114,707 | |
| $10.31 | -0.40 | -3.7% | $10.69 | $10.82 | $10.21 | 980,519 | |
| $10.71 | -0.21 | -1.9% | $10.90 | $11.01 | $10.50 | 733,702 | |
| $10.92 | -0.45 | -4.0% | $11.28 | $11.32 | $10.73 | 786,664 | |
| $11.37 | -0.125 | -1.1% | $11.49 | $11.56 | $11.16 | 717,851 | |
| $11.50 | -0.895 | -7.2% | $11.86 | $11.99 | $11.45 | 1,168,638 | |
| $12.39 | +0.35 | +2.9% | $12.05 | $12.77 | $11.97 | 1,189,495 | |
| $12.04 | -0.72 | -5.6% | $12.75 | $12.76 | $11.59 | 2,354,815 | |
| $12.76 | -4.87 | -27.6% | $17.95 | $17.95 | $12.43 | 4,848,775 | |
| $17.63 | +1.57 | +9.8% | $16.77 | $17.81 | $16.14 | 852,300 | |
| $16.06 | -2.12 | -11.7% | $18.18 | $18.24 | $16.02 | 893,100 | |
| $18.18 | +0.36 | +2.0% | $18.19 | $18.33 | $17.43 | 976,200 | |
| $17.82 | +0.36 | +2.1% | $17.60 | $18.00 | $17.59 | 769,300 | |
| $17.46 | -0.01 | -0.1% | $17.50 | $17.82 | $17.40 | 412,700 | |
| $17.47 | -0.36 | -2.0% | $17.93 | $18.17 | $17.13 | 540,000 | |
| $17.83 | -0.22 | -1.2% | $18.18 | $18.62 | $17.70 | 903,500 | |
| $18.05 | +0.79 | +4.6% | $17.01 | $18.07 | $16.89 | 984,100 | |
| $17.26 | +0.57 | +3.4% | $16.68 | $17.63 | $16.42 | 687,200 | |
| $16.69 | +0.03 | +0.2% | $16.80 | $17.18 | $16.51 | 379,200 | |
| $16.66 | -0.40 | -2.3% | $16.94 | $16.94 | $16.27 | 378,900 | |
| $17.06 | +0.13 | +0.8% | $16.88 | $17.26 | $16.58 | 514,200 | |
| $16.93 | -0.27 | -1.6% | $17.22 | $17.47 | $16.79 | 587,400 | |
| $17.20 | +0.46 | +2.7% | $16.80 | $17.66 | $16.72 | 869,400 | |
| $16.74 | +0.23 | +1.4% | $16.61 | $16.87 | $16.46 | 915,100 | |
| $16.51 | -0.81 | -4.7% | $17.27 | $17.27 | $16.43 | 765,900 | |
| $17.32 | +0.19 | +1.1% | $17.30 | $17.62 | $17.02 | 546,900 | |
| $17.13 | -0.05 | -0.3% | $17.13 | $17.49 | $16.84 | 614,600 | |
| $17.18 | -0.97 | -5.3% | $18.06 | $18.14 | $16.97 | 794,900 | |
| $18.15 | -0.24 | -1.3% | $18.29 | $18.61 | $17.96 | 803,000 | |
| $18.39 | -0.11 | -0.6% | $18.42 | $19.18 | $18.32 | 1,173,000 | |
| $18.50 | +0.58 | +3.2% | $17.77 | $18.90 | $17.30 | 1,500,800 | |
| $17.92 | +1.13 | +6.7% | $16.52 | $18.37 | $16.42 | 1,210,200 | |
| $16.79 | +0.25 | +1.5% | $16.69 | $17.37 | $16.31 | 809,800 | |
| $16.54 | -0.39 | -2.3% | $16.93 | $16.95 | $16.13 | 533,700 | |
| $16.93 | -0.03 | -0.2% | $17.25 | $17.29 | $16.84 | 805,300 | |
| $16.96 | -0.32 | -1.9% | $17.20 | $17.35 | $16.76 | 837,500 | |
| $17.28 | +0.33 | +1.9% | $17.08 | $17.56 | $16.79 | 772,500 | |
| $16.95 | +0.37 | +2.2% | $16.54 | $16.98 | $16.32 | 511,700 | |
| $16.58 | +0.28 | +1.7% | $16.57 | $16.79 | $16.16 | 473,000 | |
| $16.30 | -0.38 | -2.3% | $16.62 | $16.70 | $16.21 | 720,200 | |
| $16.68 | +0.16 | +1.0% | $16.42 | $16.79 | $15.75 | 1,302,000 | |
| $16.52 | -0.95 | -5.4% | $17.40 | $17.47 | $16.35 | 967,400 | |
| $17.47 | +0.46 | +2.7% | $17.17 | $17.47 | $16.97 | 908,300 | |
| $17.01 | +0.42 | +2.5% | $16.86 | $17.14 | $16.53 | 701,800 | |
| $16.59 | -0.27 | -1.6% | $16.70 | $16.86 | $16.40 | 2,447,400 | |
| $16.86 | +0.615 | +3.8% | $16.49 | $17.22 | $16.49 | 810,000 | |
| $16.25 | -0.195 | -1.2% | $16.43 | $16.61 | $16.04 | 1,161,600 | |
| $16.44 | -0.87 | -5.0% | $17.29 | $17.29 | $16.30 | 1,008,500 | |
| $17.31 | +0.21 | +1.2% | $17.13 | $17.57 | $17.13 | 869,800 | |
| $17.10 | -0.58 | -3.3% | $17.92 | $17.94 | $17.05 | 791,400 | |
| $17.68 | -1.65 | -8.5% | $19.17 | $19.33 | $17.60 | 980,000 | |
| $19.33 | -0.71 | -3.5% | $19.94 | $20.23 | $19.27 | 576,000 | |
| $20.04 | -0.20 | -1.0% | $20.24 | $20.25 | $19.67 | 1,061,700 | |
| $20.24 | +0.44 | +2.2% | $19.62 | $20.31 | $19.57 | 700,800 | |
| $19.80 | +0.10 | +0.5% | $19.73 | $20.00 | $19.52 | 1,686,600 | |
| $19.70 | +0.81 | +4.3% | $18.93 | $19.95 | $18.93 | 1,525,600 | |
| $18.89 | +0.67 | +3.7% | $18.15 | $18.94 | $18.04 | 980,500 | |
| $18.22 | +0.19 | +1.1% | $17.89 | $18.39 | $17.66 | 712,600 | |
| $18.03 | -0.75 | -4.0% | $18.57 | $18.73 | $17.97 | 637,800 | |
| $18.78 | -0.11 | -0.6% | $19.00 | $19.08 | $18.68 | 577,300 | |
| $18.89 | +0.21 | +1.1% | $18.59 | $18.95 | $18.33 | 524,000 | |
| $18.68 | +0.08 | +0.4% | $18.72 | $19.14 | $18.55 | 1,074,447 | |
| $18.60 | +1.21 | +7.0% | $17.82 | $19.03 | $17.50 | 1,452,369 | |
| $17.39 | +0.11 | +0.6% | $17.40 | $17.70 | $17.21 | 520,000 | |
| $17.28 | -0.24 | -1.4% | $17.29 | $17.64 | $17.19 | 1,121,800 |
- Ticker
- NASDAQ:JANX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 20 slides
Latest news
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
Nov 9, 2026
Closed $12.76 (-27.6%) on Nov 9, 2026
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 5, 2026
Closed $17.63 (+9.8%) on Nov 6, 2026
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
Nov 2, 2026
Closed $17.82 (+2.1%) on Nov 3, 2026
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Sep 14, 2026
Closed $17.31 (+1.2%) on Sep 14, 2026
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Aug 6, 2026
Closed $15.85 (-1.6%) on Aug 7, 2026
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Closed $14.18 (-2.5%) on May 8, 2026
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Apr 27, 2026
Closed $14.50 (-4.8%) on Apr 28, 2026
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
Apr 16, 2026
Closed $15.19 (+1.0%) on Apr 16, 2026
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Apr 1, 2026
Closed $14.51 (+4.4%) on Apr 1, 2026
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Feb 26, 2026
Closed $13.80 (+0.7%) on Feb 26, 2026
Janux Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 74 in all · newest Nov 9, 2026 · oldest 2021
- Decks
- 9 decks · latest November 2026
Where Janux Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:JANX · Home listing · This page | NASDAQ | United States | USD |
| BX Swiss:JANX | BX Swiss | Switzerland | CHF |
| BOATS:JANX | BOATS | United States | USD |
Valuation
EV/sales −13.3× against a median of 37.8×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$308.6M USD
- P/E
- Loss
- EV/sales
- −13.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- −78.7%
- Operating margin
- −599.3%
- Net margin
- −428.7%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.95
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics, Inc. · NASDAQ:JANX | US$616.7M | −US$308.6M | n/a | −13.3× | n/a | 0.7× | −428.7% | 0.0× | 0.95 |
| Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197 | US$647.2M | US$565.0M | n/a | 37.8× | n/a | 6.8× | −18.6% | 0.0× | n/a |
| Prime Medicine, Inc. · NASDAQ:PRME | US$645.8M | US$695.1M | n/a | 98.4× | n/a | 76.5× | n/a | 13.1× | 2.28 |
| Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT | US$638.7M | US$404.3M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.96 |
| Gubra A/S · OMXCOP:GUBRA | US$638.5M | US$533.6M | 2.6× | 1.4× | 1.7× | 4.2× | 64.1% | 0.2× | n/a |
| Kura Oncology, Inc. · NASDAQ:KURA | US$634.9M | US$152.6M | n/a | 1.9× | n/a | 35.4× | −369.3% | 0.6× | 1.30 |
| Alphamab Oncology · HKEX:9966 | US$628.9M | US$454.7M | n/a | 5.5× | n/a | 2.5× | −20.1% | 0.2× | n/a |
| Iambic Therapeutics, Inc. · NASDAQ:IAM | US$621.4M | US$369.4M | n/a | 39.2× | n/a | n/a | −820.0% | n/a | n/a |
| Olema Pharmaceuticals, Inc. · NASDAQ:OLMA | US$615.0M | US$204.6M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.25 |
| Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637 | US$608.9M | US$483.6M | n/a | 106× | n/a | 2.9× | n/a | 0.4× | n/a |
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Median of the others | US$631.9M | US$439.2M | 2.6× | 37.8× | 1.7× | 4.1× | −20.1% | 0.2× | 1.63 |
Forecasts
13 strong buy · 2 buy · 2 hold · 1 sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 33.14 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.57 · 15 analysts
- Revenue, year to Dec 2026
- 27.49M · 14 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David Campbell | Founder, President & Chief Executive Officer |
| Matt Whitmire | Vice President, Finance |
| James Pennington | General Counsel |
| Carolina Caffaro | Vice President, CMC Process Development |
| Gregory Opiteck | Vice President, Translational Medicine |
| Jenna Daly | Vice President, Clinical Operations |
| Jonathan Leith | Vice President, Project Leadership |
| Judy Vong | Vice President, Regulatory Affairs and Quality Assurance |
| Kevin Watt | Vice President, Program and Portfolio Management |
| Maria Dobek | Vice President, Accounting |
| Simon Butikofer | Vice President, Clinical Development |
| Janeen Doyle | Chief Corporate and Business Development Officer |
| Mandie Forman-Sklansky | Head of Human Resources |
| Tommy DiRaimondo | Chief Scientific Officer |
| William Go | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Ron Barrett | Chairperson |
| David Campbell | Founder, President & Chief Executive Officer |
| Eric Dobmeier | |
| Jake Simson | |
| Natasha Hernday | |
| Vickie Capps | |
| Winston Kung |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +9.8% |
| Q2 2026 | Aug 6, 2026 · After close | −1.6% |
| Q1 2026 | May 7, 2026 · After close | −2.5% |
| Q4 2025 | Feb 26, 2026 | −0.7% |
| Q3 2025 | Nov 6, 2025 · After close | −7.6% |
| Q2 2025 | Aug 7, 2025 · After close | +1.1% |
| Q1 2025 | May 8, 2025 · After close | −3.1% |
| Q4 2024 | Feb 27, 2025 | +0.9% |
| Q3 2024 | Nov 6, 2024 · After close | −1.2% |
| Q2 2024 | Aug 7, 2024 · After close | +3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −10.0% |
| Q4 2023 | Mar 8, 2024 · After close | +0.4% |
| Q3 2023 | Nov 7, 2023 · After close | +0.9% |
| Q2 2023 | Aug 8, 2023 · After close | +6.8% |
| Q1 2023 | May 9, 2023 · After close | +4.0% |
| Q4 2022 | Mar 10, 2023 · After close | −2.3% |
| Q3 2022 | Nov 10, 2022 · After close | +5.8% |
| Q2 2022 | Aug 9, 2022 · After close | +11.9% |
| Q1 2022 | May 10, 2022 · After close | +1.0% |
| Q4 2021 | Mar 18, 2022 · After close | −9.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 20 slides | November 2026 |
| Cantor Global Healthcare Conference 2026 | Conference | 21 slides | Sep 11, 2026 |
| Technical Presentation (December 2025) | Technical | 26 slides | Dec 1, 2025 |
| Investor Day (July 2025) | Investor day | 41 slides | Jul 24, 2025 |
| Corporate Update (December 2024) | Corporate update | 25 slides | Dec 2, 2024 |
| Investor Presentation (March 2024) | Investor deck | 36 slides | March 2024 |
| Investor Presentation (February 2024) | Investor deck | 31 slides | Feb 26, 2024 |
| Investor Presentation (February 2024) | Investor deck | 34 slides | Feb 26, 2024 |
| Corporate Update (July 2023) | Corporate update | 19 slides | Jul 17, 2023 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$402.5M raised · US$63 a share · BofA Securities +8 Dealers: BofA Securities (co-lead), TD Cowen (co-lead), Stifel (co-lead), Cantor (co-lead), William Blair (co-lead), Wedbush PacGrow, LifeSci Capital, BTIG, Jones Use of proceeds: Advance clinical development of its internal product pipeline and general corporate purposes | Dec 6, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Jun 10, 2021.
- Price
- US$17.00 a share
- Shares offered
- 11,400,000 shares of common stock
- Offering size
- US$193.8 million
- Underwriters' option
- Up to 1,710,000 more shares
- Underwriters
- BofA Securities, Cowen, Evercore ISI, H.C. Wainwright & Co. · In the order on the cover
- Shares delivered
- On or about Jun 15, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 16, 2021 |
| Filed publicly | May 19, 2021 |
| Amended once | Jun 7, 2021 |
| Shares registered with an exchange | Jun 9, 2021 |
| Declared effective by the SEC | Jun 10, 2021 |
| Final prospectus, with the price | Jun 11, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 11, 2021 |
| EFFECT · Notice that a registration is effective | Jun 10, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jun 10, 2021 |
| CERT · Exchange's certificate of listing | Jun 10, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 9, 2021 |
| CORRESP · Letter to the SEC | Jun 9, 2021 |
| CORRESP · Letter to the SEC | Jun 9, 2021 |
| CORRESP · Letter to the SEC | Jun 7, 2021 |
| S-1/A · Registration statement, amended | Jun 7, 2021 |
| UPLOAD · Letter from the SEC | May 28, 2021 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 19, 2021 |
| S-1 · Registration statement | May 19, 2021 |
| UPLOAD · Letter from the SEC | May 14, 2021 |
| DRS · Draft registration statement | Apr 16, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 11, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 10.0M | 10.6M | 8.08M | 8.61M | 3.64M | 0 | 0 |
| Cost of revenue | 2.03M | 2.06M | 1.96M | 75.7M | 36.6M | 13.0K | 6.00K |
| Gross profit | 7.97M | 8.53M | 6.13M | 8.61M | 3.64M | -13.0K | -6.00K |
| Research and development | 125.9M | 68.4M | 54.9M | 53.4M | 26.2M | 3.04M | 3.00M |
| Selling, general and administrative | 41.8M | 41.0M | 26.1M | 22.3M | 10.3M | 1.80M | 772.0K |
| Operating income | -157.7M | -98.8M | -73.0M | -67.1M | -32.9M | -4.84M | -3.77M |
| Depreciation and amortization | 2.03M | 2.06M | 1.96M | 841.0K | 113.0K | 13.0K | 6.00K |
| EBITDA | -155.6M | -96.8M | -71.0M | -66.3M | -32.8M | -4.83M | -3.77M |
| Interest expense | 4.03M | 370.0K | 206.0K | 233.0K | |||
| Income before tax | -113.6M | -69.0M | -58.3M | -63.1M | -32.7M | -6.78M | -4.00M |
| Income tax | 0 | 0 | 0 | -8.90M | -113.0K | -1.53M | 233.0K |
| Net income | -113.6M | -69.0M | -58.3M | -63.1M | -32.7M | -6.78M | -4.24M |
| Earnings per share, basic | -1.83 | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 | -0.10 |
| Earnings per share, diluted | -1.83 | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 52.3M | 430.6M | 19.2M | 51.4M | 35.6M | 7.81M | 658.0K |
| Short-term investments | 914.2M | 594.6M | 324.8M | 275.6M | 339.4M | 0 | |
| Receivables | 0 | 5.38M | 0 | 0 | 0 | 8.00M | 0 |
| Inventory | -2.20M | -700.0K | -200.0K | ||||
| Current assets | 975.9M | 1.03B | 349.2M | 332.4M | 377.0M | 16.1M | 658.0K |
| Property, plant and equipment | 3.85M | 4.86M | 7.00M | 7.09M | 1.41M | 155.0K | 21.0K |
| Total assets | 1.00B | 1.06B | 380.4M | 364.0M | 379.8M | 16.2M | 679.0K |
| Accounts payable | 4.97M | 4.03M | 2.42M | 2.16M | 2.46M | 428.0K | 267.0K |
| Current liabilities | 25.0M | 17.5M | 13.0M | 16.5M | 12.8M | 3.18M | 4.63M |
| Total debt | 22.1M | 23.0M | 24.5M | 25.3M | 194.0K | 4.00M | |
| Total liabilities | 44.7M | 38.7M | 36.1M | 43.3M | 13.5M | 9.23M | 8.62M |
| Shareholders' equity | 956.8M | 1.02B | 344.3M | 320.7M | 366.3M | -14.6M | -7.94M |
| Shares outstanding | 60.4M | 59.1M | 46.3M | 41.6M | 41.2M | 1.05M | 41.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -82.2M | -43.8M | -50.6M | -42.9M | -17.0M | -4.37M | -3.83M |
| Capital spending | -1.04M | -359.0K | -1.85M | -6.45M | -1.48M | 0 | -1.48M |
| Free cash flow | -83.3M | -44.2M | -52.4M | -49.4M | -18.5M | -4.37M | -3.83M |
| Cash from investing | -301.0M | -258.0M | -41.2M | 58.3M | -341.0M | 0 | -341.0M |
| Cash from financing | 4.95M | 713.2M | 59.5M | 500.0K | 386.5M | 11.5M | 4.00M |
| Share buybacks | -347.0K | 204.2M | |||||
| Change in cash | -378.3M | 411.4M | -32.2M | 15.8M | 28.6M | 7.16M | 172.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 23, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 22, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 28, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 19, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 23, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 21, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Jan 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 5, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 5, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 3, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 28, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 28, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 28, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 25, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 25, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Oct 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 24, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 23, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Oct 23, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 26, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 16, 2024 | Big-stake notice | SEC |
This page holds 200 of 443 filings. Open Filings
Cap table
Built by 6ix from Janux Therapeutics, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 61,183,417
- Fully diluted
- 61,183,417
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 61,183,417 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 61,183,417 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Jun 10, 2021 |
| Eric Dobmeier Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 14, 2021 · Past) | Director · Since at least Jul 19, 2024 |
| Jake Simson Other companies: Septerna, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Jun 11, 2026 |
| Natasha Hernday Other companies: XOMA Royalty Corporation (Director · Since at least May 21, 2026) | Director · Since at least Jun 11, 2026 |
| Andrew Hollman Meyer | Chief Business Officer · Since at least Jan 2, 2024 |
| Byron Robinson | Chief Strategy Officer · Mar 1, 2022 – Jan 2, 2025 · Past |
| Carolina Caffaro | Vice President, CMC Process Development · Since at least Nov 5, 2026 |
| Charles M Winter | Chief Technical Officer · Since at least Jan 2, 2024 |
| David Campbell | Founder, President & Chief Executive Officer · Since at least Jul 31, 2026 |
| Gregory Opiteck | Vice President, Translational Medicine · Since at least Nov 5, 2026 |
All 29 people
| Person | Seat |
|---|---|
| James Pennington | General Counsel · Since at least Nov 5, 2026 |
| Janeen Doyle | Chief Corporate and Business Development Officer · Since at least May 14, 2025 |
| Jenna Daly | Vice President, Clinical Operations · Since at least Nov 5, 2026 |
| Jonathan Leith | Vice President, Project Leadership · Since at least Nov 5, 2026 |
| Judy Vong | Vice President, Regulatory Affairs and Quality Assurance · Since at least Nov 5, 2026 |
| Kevin Watt | Vice President, Program and Portfolio Management · Since at least Nov 5, 2026 |
| Mandie Forman-Sklansky | Head of Human Resources · Since at least Nov 5, 2026 |
| Maria Dobek | Vice President, Accounting · Since at least Aug 8, 2024 |
| Matt Whitmire | Vice President, Finance · Since at least Nov 4, 2026 |
| Ronald W Barrett | Director · Since at least Jun 11, 2025 |
| Ron Barrett | Chairperson · Since at least Jun 12, 2026 |
| Simon Butikofer | Vice President, Clinical Development · Since at least Sep 14, 2026 |
| Thomas DiRaimondo | Chief Scientific Officer · Since at least Jan 1, 2024 |
| Tommy DiRaimondo | Chief Scientific Officer · Since at least Feb 17, 2026 |
| Vickie Capps | Director · Since at least Jun 12, 2026 |
| Wayne Godfrey | Chief Medical Officer · Jun 10, 2021 – Jan 3, 2023 · Past |
| William Go | Chief Medical Officer · Since at least Feb 26, 2026 |
| Winston Kung | Director · Since at least Jun 12, 2026 |
| Zachariah McIver | Chief Medical Officer · Since at least Jan 1, 2025 |
Log in to ask 6ix AI your own questions about Janux Therapeutics, Inc.